GSK to Cap Asthma, COPD Inhaler Costs to $35 Per Month for Eligible Patients

The out-of-pocket costs for GSK asthma and chronic obstructive pulmonary disease (COPD) inhalers will be capped at $35 per month for eligible patients, according to the Company.

The medications in the program include Advair Diskus (fluticasone propionate and salmeterol inhalation powder), Advair HFA (fluticasone propionate and salmeterol inhalation aerosol), Anoro Ellipta (umeclidinium and vilanterol inhalation powder), Arnuity Ellipta (fluticasone furoate inhalation powder), Breo Ellipta (fluticasone furoate and vilanterol inhalation powder), Incruse Ellipta (umeclidinium inhalation powder), Serevent Diskus (salmeterol xinafoate inhalation powder), Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder), and Ventolin HFA (albuterol sulfate inhalation aerosol).

“GSK is committed to bringing innovation and accessibility to patients with respiratory illnesses,” said Maya Martinez-Davis, President, US Commercial, GSK. “In the US, we already provide significant rebates and discounts for our products, as well as patient assistance programs, to help bring down costs and this new commitment, combined with our existing offerings, will help even more patients living with asthma or COPD.”

According to the Company, the new program will begin no later than January 1, 2025.